Quinoxaline 1,4-di-N-oxide and the Potential for Treating Tuberculosis by Vicente, E. (Esther) et al.
 
Quinoxaline 1,4-di-N-oxide and the Potential for Treating 
Tuberculosis 
E. Vicente1, R. Villar1*, B. Solano1, A. Burguete1, S. Ancizu1, B. Zarranz1, A. Jaso1, A. 
Marín1, S. Pérez-Silanes1, I. Aldana1, R. Goldman2, A. Monge1 
Unidad de Investigación y Desarrollo de Medicamentos, Centro de Investigación en Farmacobiología 
Aplicada (CIFA), University of Navarra, C/ Irunlarrea s/n, 31008 Pamplona, Spain1, National Institutes 
of Health, Division of Microbiology and Infectious Diseases, Bethesda, MD, USA2 
 
 
 
 
 
 
 
 
Keywords: Tuberculosis, quinoxaline 1,4-di-N-oxide, Mycobacterium. 
 
*Address correspondence to this author at Unidad de Investigación y Desarrollo de 
Medicamentos, Centro de Investigación en Farmacobiología Aplicada (CIFA), University of 
Navarra, C/ Irunlarrea s/n, 31008 Pamplona, Spain. Tel.: +34 948 425653; Fax +34 948 
425652; e-mail: cifa@unav.es 
 
 
 
ABSTRACT 
New drugs active against drug-resistant tuberculosis are urgently needed to extend the 
range of TB treatment options to cover drug resistant infections. Quinoxaline derivatives show 
very interesting biological properties (antibacterial, antiviral, anticancer, antifungal, 
antihelmintic, insecticidal) and evaluation of their medicinal chemistry is still in progress. In 
this review we report the properties and the recent developments of quinoxaline 1,4-di-N-
oxide derivatives as potential anti-tuberculosis agents.  Specific agents are reviewed that 
have excellent antitubercular drug properties, are active on drug resistant strains and non-
replicating mycobacteria.  The properties of select analogs that have in vivo activity in the low 
dose aerosol infection model in mice will be reviewed. 
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INTRODUCTION 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a respiratory transmitted 
disease affecting nearly 32% of the world’s population, more than any other infectious 
disease. Since the beginning of human history tuberculosis has been a companion of 
mankind. However, the impact of tuberculosis on morbidity and mortality has varied widely 
during the centuries. There were an estimated 8.8 million new TB cases in 2005. A total of 1.6 
million people died of TB, including 195 000 patients infected with HIV [1]. 
Since the beginning of the clinical treatment of tuberculosis with streptomycin it was 
observed that the bacillus was capable of rapidly developing drug resistance [2]. By the 
1950s drug combination regimens were established to prevent drug resistance [3]. Currently, 
multidrug-resistant (MDR) TB presents a high incidence, with rates varying widely between 
different countries and regions [4]. The continuing emergence of multidrug-resistant strains of 
M. tuberculosis (MDR-TB) will inevitably make it more difficult in the future to control TB in the 
global setting [5]. Another important issue related to the increasing spread of tuberculosis is 
the coexistence of HIV with TB. HIV infected patients who progress to AIDS are at high risk 
for infection with TB and other mycobacteria (such as M. avium). While M. avium does not 
usually cause disseminated disease in healthy individuals, in immunocompromised patients, 
such as AIDS, disseminated disease is common [6]. So the pandemic of AIDS and the 
evidence of its association with tuberculosis is now of serious concern [7]. The development 
of resistance by M. tuberculosis to commonly used anti-tuberculosis drugs, the increasing 
incidences of disease in immuocompromised patients, and longer durations of therapy that 
are required as a result of resistance development, highlights the need for new drugs to 
extend the range of effective TB treatment options.  
The Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) was 
established in 1994 by the National Institute of Allergy and Infectious Diseases [8] in order to 
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provide drug testing facilities to help in the discovery of new antitubercular drugs. The 
program, managed by Southern Research Institute (Birmingham, AL), assists commercial, 
academic and government laboratories worldwide in identifying new chemical classes of 
compounds for evaluation in in vitro and in vivo models. The purpose of the screening 
program is to provide a resource whereby new experimental compounds can be tested for 
their ability to inhibit the growth of virulent M. tuberculosis. These screening activities have 
resulted in several promising agents that have reached advanced stages of testing [9]. Chart 
1 shows the preliminary levels of biological assays and cut-offs applied by TAACF for 
progression of the compounds in tuberculosis drug screening program. 
The quinoxaline derivatives are a class of compounds that show very interesting 
biological properties and there is active interest in their medicinal chemistry. The oxidation of 
both nitrogens of this heterocyclic system, in order to obtain quinoxaline 1,4-di-N-oxide 
derivatives, increases the number of biological properties enormously [10]. In fact, the 
quinoxaline 1,4-di-N-oxides were known as potent antibacterial agents since the 1940s [11-
15], and subtherapeutic levels have been used as animal growth promotors in feed additives 
(Figure 1) [16-20]. Specific derivatives also show selective cytotoxicity against hypoxic cells 
present in solid tumors [21]. Furthermore, recent studies have demonstrated that quinoxaline 
1,4-di-N-oxides are endowed with antimycobacterial, antiprotozoal [22,23], anticandida 
[24,25] activities and mutagenic properties [26-28], depending on specific chemical features. 
In the last two decades many mono- and di- N-oxides of the quinoxaline ring subunit were 
reported [29]. Data from studies of quinoxaline 1,4-di-N-oxide derivatives as antitubercular 
drug candidates has shown that specific derivatives show hold promise in the treatment of TB 
[30,31]. 
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GENERAL BACKGROUND 
Isoniazid and pyrazinamide are based on pyridine and pyrazine rings respectively, both 
classical bioisosters. The fusion of these aromatic heterocycles with a benzene moiety leads 
to benzo[b]pyridine and benzo[b]pyrazine, also know as quinoline and quinoxaline rings. An 
example of quinoline derivatives is compound TMC207 (also known as R020790) which is in 
clinical trials for treating tuberculosis [32]. Quinolone derivatives arise from oxidation of 
quinoline moiety; this heterocycle is the main scaffold of well-know fluoroquinolones such as 
ciprofloxacin [33]. As shown figure 2, our design of new antitubercular drug is based on 
chemical structural resemblance. 
In addition, quinoxalines and their mono- and di-N-oxide derivatives display a broad 
range of biological activities [10] and quinoxaline di-N-oxides are known to undergo 
bioreductions under hypoxia causing DNA damage [26-28] and likely other cellular damage. 
Given the known activity of other classes of bioreductive agents (e.g. metronidazole, PA-824 
and OPC-67683), it appeared logical to us to evaluate our group of structures against 
mycobacteria [9]. 
Over 87,000 compounds have been supplied to TAACF, of which only 0.9% have 
shown a good in vitro activity/toxicity ratio [9]. One of five lead compound series which were 
identified and are currently been pursued under the TAACF program is the series of 
quinoxaline 1,4-di-N-oxide derivatives. Over 500 quinoxaline derivatives from our laboratory 
were tested by the TAACF program, including simple substituted quinoxalines and their 
corresponding 1,4-di-N-oxides. Many of these compounds possess excellent antitubercular 
activity, and the range of possible substituents affords an opportunity to tailor both the 
pharmacokinetic and activity profiles [9]. 
As a part of our antituberculosis research project, we have synthesized different series 
of quinoxaline-1,4-di-N-oxide derivatives, with a great variety of substituents in positions 2, 3, 
6 and 7 (Figure 3). Regarding the 2 position, where the main group is linked, our team has 
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principally worked with carbonitrile, amide, ketone and ester derivatives. The groups studied 
in position 3 are, among others, methyl, amine, trifluoromethyl, piperazinyl and phenyl groups. 
Finally, the substitutions of the hydrogens of positions R6 and/or R7 by fluorine, chlorine, 
methyl, trifluoromethyl and methoxy groups allowed us to obtain a great variety of 
compounds. These studies have facilitated a wide-ranging structure-activity relationship 
(SAR) analysis. 
The first publications regarding quinoxaline derivatives as anti-Mycobacterium agents 
date back to the end of the 1990s [34-36]. Herein, our group reported interesting results of 2-
quinoxalinecarbonitrile derivatives obtained from the first screening; Carta’s team did the 
same with quinoxaline-2-one derivatives [37]. During these past few years, our group studied 
the influence of the 1,4-di-N-oxide groups in quinoxaline ring on the antimycobacterial activity, 
confirming their importance to increase the activity [34-36].  
In the early 2000s, positive results from further studies were obtained and several new 
quinoxaline 1,4-di-N-oxide derivatives were synthesized and tested against Mycobacterium 
tuberculosis. The 2-quinoxalinecarbonitrile derivatives appeared to be quite toxic [38,39]; 
thus, the replacement of the carbonitrile group with a carboxamide [40], acetyl, benzoyl [41] 
or carboxylate groups [42] was proposed.  
A group of thirty-one 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives was 
prepared and tested [40]. Eight showed a MIC value lower than 6.25 µg/mL although only 3 
presented enough selectivity and good results in macrophage assay in order to merit 
continuation of their study. We should point out the interesting antimycobacterial activities 
shown by certain 3-methyl-N-phenylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives, 
particularly the compounds with a chlorine atom in 7 position (3) and corresponding 
nonsubstituted derivatives (1 and 2) which showed the best results (Figure 4). With regard to 
the benzene moiety, greater effectiveness resulted for the ortho-methyl substituents (2 and 
3). 
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Among twenty-seven 2-acetylquinoxaline 1,4-di-N-oxide and seven 2-
benzoylquinoxaline 1,4-di-N-oxide derivatives [41], eighteen demonstrated MIC values equal 
or better than the first cut-off established by the TAACF. Six of these derivatives also showed 
good selectivity and maintained activity in the macrophage assay, among which stand out 
compounds 4-6 (Figure 5), exhibiting EC90/MIC values between 0.79 and 3.13. 
Twenty-two of the twenty-nine 2-quinoxalinecarboxylate 1,4-di-N-oxide derivatives 
evaluated possessed improved MIC values [42]. In addition, fifteen were selective as 
assessed by the cytotoxicity assay and were active in the macrophage assay. The results 
from the in vitro assays show that of the series tested ethyl and benzyl 3-methylquinoxaline-2-
carboxylate 1,4-di-N-oxide derivatives with the chlorine group in position 7 of the benzene 
moiety (8 and 10) and the unsubstituted derivatives (7 and 9) had the best antimycobacterial 
activity, showing EC90/MIC values between 0.01 and 2.30 (Figure 6). These new quinoxaline 
1,4-di-N-oxide derivatives emerged as new lead candidates for the treatment against 
tuberculosis because of their potency, selectivity and low cytotoxicity. 
Meanwhile, other groups continued their work with reduced quinoxaline derivatives as 
antimycobacterial agents [43-45]. Kunes et al. studied a series of 3-methyl-2-
alkylsulfanylquinoxalines, but none were active against M. tuberculosis. Seitz and coworkers 
prepared 9 quinoxaline-2-carboxylates, but only two achieved the MIC values of 6.25 g/mL; 
Guillon´s group focused on pyrrolo[1,2-a]quinoxaline-carboxylic acid hydrazide derivatives 
and, again, only two compounds reached the first cut-off (MIC<6.25 g/mL).  
Carta’s team published a series of 3-methylquinoxaline 1,4-di-N-oxide derivatives with a 
phenylthio, phenylsulfonyl or phenylsulfinyl linked in R2 position of quinoxaline subunit. They 
completed this work studying 6,7-difluoroquinoxaline derivatives, analogues to the previous 
compounds, in which the phenylthio group was substituted for benzylamino or phenylamino 
(Figure 7). The series of 3-methyl-2-phenylthioquinoxaline 1,4-di-N-oxide derivatives 
presented the best MIC data, ranging between 0.39 and 0.78 µg/mL, whereas the oxidation of 
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sulphur bridge to yield phenylsulfinyl and phenylsulfonyl derivatives or its replacement with 
benzylamino or phenylamino group slightly reduces its activity [24,25]. 
RECENT DEVELOPMENTS 
These in vitro results indicate that 1,4-di-N-oxide quinoxalines hold promise for the 
treatment of tuberculosis. Therefore, an extended evaluation of the in vitro and in vivo 
antitubercular activity of most interesting quinoxaline 1,4-di-N-oxide derivatives was 
performed.  
Amide derivatives 
MIC values for the most potent amide derivatives from our previous studies (1-3) 
(Figure 4) were determined against different single-drug resistant strains of M. tuberculosis. In 
general, the three derivatives showed good MIC values against resistant strains. The MBCs 
against strain H37Rv of compounds 1 and 2 were determined. Derivative 1 could be 
considered bactericidal but, on the other hand, compound 2, which showed higher MBC/MIC 
ratios for H37Rv, indicated bacteriostatic rather than bactericidal activity [30]. 
Ketone derivatives 
The ketone derivatives 4-6 (Figure 5) were subjected to the following set of tests: 
determination of MIC against different SDR strains of M. tuberculosis, MBC and in vivo 
efficacy testing, including the determination of oral bioavailability and the MTD. Almost all of 
these derivatives displayed good inhibitory activity against resistant strains. Results showed 
that the most moderate activity was observed against the CIP-resistant strain. The 
susceptibilities of RIF-, TAC-, EMB- and PAS resistant strains were comparable to that of 
H37Rv, with ratios of MICs against resistant and non-resistant strains about 1. This indicates 
that there is no cross-resistance with the current anti-TB drugs supporting the premise that 
1,4-di-N-oxide quinoxaline derivatives have a novel mode of action unrelated to the currently 
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used antitubercular drugs. These results are promising for the development of new effective 
compounds against the growing number of drug resistant strains [30]. Compounds 4 and 6 
could be considered to be bactericidal due to the low MBC/MIC ratios obtained [30].  
In addition, specific derivatives were further evaluated in a series of in vivo assays and 
compound 6 (designated TAACF 118845) was active in reducing CFU counts in both the lung 
and spleen of infected mice following oral administration (Figure 8). This in vivo efficacy is 
comparable to clinically used TB drugs, although a relatively high dose of compounds was 
required to obtain equivalent reductions in lung CFU [30]. Compound 6 was active in vivo via 
oral administration when dosed at 100 or 300 mg/kg and in vivo cidal activity was indicated at 
300mg/kg dosing (i.e. CFU counts following 9 days of therapy were lower that the CFU 
counts at the initiation of therapy, Figure 8). 
This compound is most likely bioreduced to an active metabolite and is active on PA-
824 resistant M. bovis, thereby indicating that the pathway of bioreduction/activation was 
different from PA-824, a bioreducible nitroimidazole in clinical trials [33,46]. In addition 
compound 6 was tested against non-replicating bacteria (NRP) adapted to low oxygen and 
showed very good activity, indicating that activation occurred in both growing and non-
replicating bacteria leading to cell death [30].  
Therefore, the activity of compound 6 is unique in that it is 1) bactericidal; 2) active on 
single-drug resistant strains, 3) and more importantly active on poly-drug resistant clinical 
isolates, MDR-TB, including strains with resistance to additional TB drugs and quinolones; 4) 
orally bioavailable and strongly active in vivo, in a murine model of tuberculosis infection; 5) 
active against PA-824 resistant strains of M. bovis with defined resistance determinants; and 
6) active on non-replicating persistent mycobacteria. This later activity may prove important 
for attaining cures in a shorter amount of time, and this is being further evaluated in vitro and 
in vivo [30]. 
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Ester derivatives 
Following the protocol for the ketone derivatives, several ester compounds were 
subjected to the same in vitro and in vivo assays. 
The MIC against different single-drug resistant strains of M. tuberculosis and in vivo 
efficacy testing of the most potent compounds from previous studies were evaluated. Similar 
to the results for the ketone derivatives there is little to no cross-resistance with the current 
anti-TB drugs as all compounds showed ratios of MICs against resistant and non-resistant 
strains of about 1 [31].  
Compound 8 is most likely bioreduced to an active metabolite and is active on PA-824 
resistant M. bovis, thereby indicating that the pathway of bioreduction/activation was different 
from PA-824, a bioreducible nitroimidazole in clinical trials [33,46].  Quinoxaline N-oxides are 
likely activated via bioreduction in bacteria. Compound 8 is most likely bioreduced to an 
active metabolite and is active on PA-824 resistant M. bovis, thereby indicating that the 
pathway of bioreduction/activation was different from PA-824via of the nitroimidazole PA-824 
was used to compare if compound 8 was activated through the same pathway. Again, the 
quinoxaline derivative 8 was active on all PA-824 resistant M. bovis strains tested showing 
lack of cross-resistance and supporting a different pathway of drug activation. This compound 
also showed activity under anaerobic conditions in a Low Oxygen Recovery Assay (LORA). 
The in vivo activity of ethyl 7-chloroquinoxaline derivative (8, designated TAACF 
151985) was evaluated at oral doses of 25, 100 and 300 mg/kg. This compound was active in 
the lung and spleen (Figure 9) at 100 and 300 mg/kg with a reduction of the CFU of 2.03 and 
5.58 (lung) and 2.72 and 5.51 (spleen), respectively [31]. As with compound 6, compound 8 
appeared cidal in vivo when dosed at 300mg/kg (Figure 9). 
Several structural modifications were introduced onto the lead compounds of the series 
of 3-methylquinoxaline-2-carboxylate 1,4-di-N-oxide derivatives [47]. Homologation of the 
substituents linked at C-3 of quinoxaline scaffold was obtained by the replacement of a 
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methyl with a phenyl group, keeping the ethyl carboxylate group linked to C-2 of the 
quinoxaline subunit. Variations of the electronic profile of the group W linked to the para 
position of the phenyl moiety were carried out [48]. All of the modifications were conducted in 
order to establish the contributions of electronic and steric parameters for the optimization of 
the lead compounds. Certain parameters of potency, cytotoxicity and selectivity (levels 1 and 
2) were established for the fourteen synthesized derivatives. The unsubstituted derivatives in 
positions R6/R7 and the 7-methyl derivative demonstrated selectivity indexes greater than the 
established cut-off (SI>10) and were selected for more additional studies. One compound 
with unique activity is ethyl 3-(4’-fluoro)phenylquinoxaline-2-carboxylate 1,4-di-N-oxide, 11 
(Figure 10) [47]. 
Other derivatives 
Our research group designed other quinoxaline 1,4-di-N-oxide derivatives [49] in order 
to combat other diseases such as malaria [50-54] and cancer [55,56] which were also 
assayed as antimycobacterial candidates. 
Twenty seven 2-alkylcarbonyl- and thirty 2-arylcarbonyl-3-trifluoromethylquinoxaline 
1,4-di-N-oxide derivatives, designed as anticancer [55,56] and antiplasmodial agents [51,52], 
were tested against M. tuberculosis. Among these 57 compounds, only eight of them did not 
pass the first screening but almost all of them were not selective enough (SI<10) to move 
forward. The four derivatives with SI>10 were all alkylcarbonyl derivatives (the least potent 
against cancer cell lines), outstanding 6,7-dichloro-2-isobutyryl-3-trifluoromethylquinoxline 
1,4-di-N-oxide, 12 (Figure 9). 
Our group synthesized seventy two 3-arylquinoxaline-2-carbonitrile 1,4-di-N-oxide 
derivatives, designed as antiplasmodial agents [50,53,54]. The activity against M. 
tuberculosis of all of them were established, showing that sixty-nine derivatives attained the 
first cut-off (MIC <6.25 g/mL). Moreover, forty-five of these sixty-nine compounds showed an 
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MIC value equal to or less than 0.2 µg/mL, a value on the order of MIC of rifampicin (RIF). 
Cytotoxicity and selectivity of thirty-seven analogs were determined revealing that the 
fluorinated derivatives (13-18) were the least cytotoxic and the most selective compounds 
(Figure 10). One compound of particular interest is 7-methyl-3-(4’-fluoro)phenylquinoxaline-2-
carbonitrile 1,4-di-N-oxide, 14, with MIC < 0.2 µg/mL and SI > 500 [47]. 
Mycobacterium avium 
Infections caused by M. tuberculosis and M. avium complex are the most commonly 
reported opportunistic bacterial infections in people with HIV disease [57]. M. avium is a 
human pathogen that causes infection in immunocompetent as well as immunocompromised 
patients [58]. The TAACF has tested some of our selected compounds for activity against M. 
avium but only one was active. This compound, 6, the ethyl 7-chloro-3-methylquinoxaline-2-
carboxylate 1,4-di-N-oxide demonstrated MIC  8 µg/mL for 4 of the 5 strains tested. The 
reason for lack of, or reduced activity on M. avium could be due to differences in potential 
activating enzymes and or uptake of compounds into the bacteria. 
CONCLUSIONS 
Over the past years quinoxaline 1,4-di-N-oxide derivatives were found to possess activity 
against M. tuberculosis. Continued evaluation of in vitro antimycobacterial activity and 
cytotoxicity of our quinoxaline 1,4-di-N-oxide series, allowed identification of novel 
antitubercular candidates based on their potency, selectivity and low cytotoxicity, making 
them valid new lead for synthesizing additional analogs that might improve the antitubercular 
activity both in vitro and in vivo. Recently some select analogs were found active against a 
panel of single-drug-resistant strains and in the TAACF macrophage model. Two derivatives, 
compounds 6 and 8, proved efficacious in vivo in a murine model of low dose aerosol 
infection. Moreover, theses two compounds also showed activity against non-replicating 
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bacteria. If the bactericidal activity and activity on NRP bacteria in vitro translate to in vivo 
conditions, quinoxaline 1,4-di-N-oxides may lead to shortened therapy, because the presence 
of NRP bacteria is believed to be a major factor responsible for the prolonged nature of 
antitubercular therapy. In conclusion, quinoxaline 1,4-di-N-oxides represent a new class of 
orally active antitubercular drugs. 
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ABBREVIATIONS 
AIDS = Acquired immunodeficiency syndrome 
CFU = Colony-forming unit 
CIP = Ciprofloxacin 
EC = Effective concentration 
EMB = Ethambutol 
GI = Growth inhibition 
HIV = Human immunodeficiency virus 
INH = Isoniazid 
LORA = Low oxygen recovery assay 
MBC = Minimum bactericidal concentration 
MDR-TB = Multiple drug resistant tuberculosis 
MIC = Minimum inhibitory concentration 
MTD = Maximum tolerated dose 
NIAID = National Institute of Allergy and Infectious Diseases 
NRP = Non-replicating persistent 
PAS = p-aminosalicylic acid 
RIF = Rifampin 
SDR = Single drug resistant 
SI = Selectivity index 
TAACF = Tuberculosis Antimicrobial Acquisition and Coordinating Facility 
TAC = Thiacetazone 
TB = Tuberculosis 
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Chart 1.  Testing levels and values used for moving compounds forward by TAACF. Level 1 
testing determines the percent of growth inhibition (GI) for compounds; drugs having a GI of > 
90% or greater advance to level 2. In Level 2 compounds are further selected on the basis 
MIC determination and selectivity index (SI) and compounds with SI  10 move forward to 
more advanced testing.  Level 3 measured activity against M. tuberculosis in the macrophage 
infection model and the EC90/MIC is determined.  Level 3 also included testing against the 
single drug resistant strains (SDR-MIC) assays [9].  Together these data determine which 
compounds are testing for efficacy in animal models. 
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Figure 1. Chemical structures of quinoxaline 1,4-di-N-oxides used as animal growth 
promotors. 
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Figure 2. Scheme of chemical structural resemblance of antitubercular drugs. 
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Figure 3. General structure of quinoxaline 1,4-di-N-oxide. 
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Figure 4. 3-methyl-N-phenylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. 
 






%&%$'($µ)*+
,%-%
./*%&%'0





3







%&%$'($%µ)*+
,%-%
./*%&%'/

%&%'0%µ)*+
,%-%
./*%&%$'($
 
 
Figure 5. 2-acetylquinoxaline 1,4-di-N-oxide derivatives. 
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Figure 6. Ethyl and benzyl 3-methylquinoxaline-2-carboxylate 1,4-di-N-oxide derivatives. 
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Figure 7. General structure of quinoxaline 1,4-di-N-oxide derivatives published by Carta’s 
team in 2002 and 2004. 
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Figure 8. Dose response in vivo for compound 6, designed TAACF 118845.  Mice were 
infected via low dose aerosol on day 0.  Following 15 days to allow the infection to establish, 
therapy was initiated once per day for 9 days.  The next day mice were sacrificed and lung 
and spleen removed and homogenized and plated for CFU determination.  CFU in infected 
mice on day 15 (the start of therapy) were also determined to establish the infectious burden 
at the initiation of therapy. 
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Figure 9. Dose reponse in vivo for compound 8, designated TAACF 151985.  Procedures 
were identical to Figure 8. 
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Figure 10. In vitro lead-compounds of new series of quinoxaline 1,4-di-N-oxides. 
